Your browser doesn't support javascript.
loading
Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma.
Wang, R; Jing, G; Lv, J; Song, H; Li, C; Wang, X; Xia, W; Wu, Y; Ren, G; Guo, W.
Afiliação
  • Jing G; The Ninth People's Hospital Affiliated with Shanghai Jiaotong University, Shanghai Key Laboratory of Stomatology, Shanghai, China.
  • Lv J; The Ninth People's Hospital Affiliated with Shanghai Jiaotong University, Shanghai Key Laboratory of Stomatology, Shanghai, China.
  • Song H; The Ninth People's Hospital Affiliated with Shanghai Jiaotong University, Shanghai Key Laboratory of Stomatology, Shanghai, China.
  • Li C; The Ninth People's Hospital Affiliated with Shanghai Jiaotong University, Shanghai Key Laboratory of Stomatology, Shanghai, China.
  • Wang X; Nanjing Medical University Affiliated with Wuxi People's Hospital, Wuxi City, China.
  • Xia W; The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Wu Y; The Ninth People's Hospital Affiliated with Shanghai Jiaotong University, Shanghai Key Laboratory of Stomatology, Shanghai, China.
  • Ren G; The Ninth People's Hospital Affiliated with Shanghai Jiaotong University, Shanghai Key Laboratory of Stomatology, Shanghai, China.
  • Guo W; The Ninth People's Hospital Affiliated with Shanghai Jiaotong University, Shanghai Key Laboratory of Stomatology, Shanghai, China.
Genet Mol Res ; 14(4): 11944-54, 2015 Oct 05.
Article em En | MEDLINE | ID: mdl-26505342
Two major subtypes of melanoma include cutaneous melanoma and mucosal melanoma. The latter type is rare and usually occurs in the head and neck region. High-dose interferon-α-2b (IFN-α-2b) has proven effective in the treatment of cutaneous melanoma. Recently, a regimen of temozolomide plus cisplatin was reported more likely to improve relapse-free survival and overall survival than high-dose IFN-α-2b for mucosal melanoma. We conducted this study to analyze the therapeutic effect of high-dose IFN-α-2b for patients with oral mucosal melanoma who had received prior chemotherapy. One hundred and seventeen patients with stage III-IVa oral mucosal melanoma who had received chemotherapy were analyzed. The overall survival and relapse-free survival were compared between the patients with/without high-dose IFN-α-2b. The results indicate that the IFN-α-2b treatment group had a longer relapse-free survival rate (P = 0.0169) as compared to the control group. However, the overall survival was not significant between the two groups (P = 0.096), except in patients in stage IVa, whose overall survival increased by 20 months (P = 0.0146). The adverse reactions included a drug-induced influenza-like syndrome, gastrointestinal responses, myelosuppression, and hepatoxicity, which were predominantly of grade 1-2 and reversible. Thus, patients with resected oral mucosal melanoma, even those who have received chemotherapy, could benefit from the treatment of high-dose IFN-α-2b.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Interferon-alfa / Melanoma Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Genet Mol Res Assunto da revista: BIOLOGIA MOLECULAR / GENETICA Ano de publicação: 2015 Tipo de documento: Article País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Interferon-alfa / Melanoma Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Genet Mol Res Assunto da revista: BIOLOGIA MOLECULAR / GENETICA Ano de publicação: 2015 Tipo de documento: Article País de publicação: Brasil